Nephrology and Hypertension

Clinical specialties: acute kidney injury, nephrotic syndrome, kidney stones

Visit the Devarajan Lab.

Premedical Studies: Bombay University, India, 1979.

MD: Bombay University, India, 1985.

Czech KA, Bennett M, Devarajan P. Distinct metalloproteinase excretion patterns in focal segmental glomerulosclerosis. Pediatr Nephrol. 2011 Jul 1.

Askenazi DJ, Koralkar R, Levitan EB, Goldstein SL, Devarajan P, Khandrika S, Mehta RL, Ambalavanan N. Baseline Values of Candidate Urine Acute Kidney Injury (AKI) Biomarkers Vary by Gestational Age in Premature Infants. Pediatr Res. 2011 Jun 3.

Abraham BP, Frazier EA, Morrow WR, Blaszak RT, Devarajan P, Mitsnefes M, Bryant JC, Sachdeva R. Cystatin C and neutrophil gelatinase-associated lipocalin as markers of renal function in pediatric heart transplant recipients. Pediatr Transplant. 2011 Apr 25.

Sundaram N, Bennett M, Wilhelm J, Kim MO, Atweh G, Devarajan P, Malik P. Biomarkers for early detection of sickle nephropathy. Am J Hematol. 2011 Jul;86(7):559-66.

Devarajan P, Krawczeski C. In reply to 'antifibrinolytic use during cardiac and hepatic surgery makes tubular proteinuria-based early biomarkers poor tools to diagnose perioperative acute kidney injury'. Am J Kidney Dis. 2011 Jun;57(6):960-1.

Piyaphanee N, Ma Q, Kremen O, Czech K, Greis K, Mitsnefes M, Devarajan P, Bennett MR. Discovery and initial validation of α 1-B glycoprotein fragmentation as a differential urinary biomarker in pediatric steroid-resistant nephrotic syndrome. Proteomics Clin Appl. 2011 Jun;5(5-6):334-42.

Li S, Krawczeski CD, Zappitelli M, Devarajan P, Thiessen-Philbrook H, Coca SG, Kim RW, Parikh CR; for the TRIBE-AKI Consortium. Incidence, risk factors, and outcomes of acute kidney injury after pediatric cardiac surgery: A prospective multicenter study. Crit Care Med. 2011 Jun;39(6):1493-1499.

Krawczeski CD, Woo JG, Wang Y, Bennett MR, Ma Q, Devarajan P. Neutrophil gelatinase-associated lipocalin concentrations predict development of acute kidney injury in neonates and children after cardiopulmonary bypass. J Pediatr. 2011 Jun;158(6):1009-1015.e1.

Basu RK, Devarajan P, Wong H, Wheeler DS. An update and review of acute kidney injury in pediatrics. Pediatr Crit Care Med. 2011 May;12(3):339-47.

Devarajan P. Biomarkers for the early detection of acute kidney injury. Curr Opin Pediatr. 2011 Apr;23(2):194-200.

Faculty

Michael R. Bennett, PhD Director, Biomarker Laboratory

research interests include developing early diagnostic markers for pediatric diseases, such as acute kidney injury, nephrotic syndrome and lupus nephritis. Dr. Bennett is also interested in unraveling the etiology of focal segmental glomerulosclerosis by studying both the underlying genetic and proteomic patterns associated with the disease.

513-636-8349 michael.bennett@cchmc.org

High Res

Michael R. Bennett, PhD

Director, Biomarker Laboratory

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-636-8349

Email michael.bennett@cchmc.org

Show All

Research Interests

Diagnostic markers for pediatric diseases; acute kidney injury; nephrotic syndrome; lupus nephritis; focal segmental glomerulosclerosis; mechanisms of neurologic disease

Research Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

PhD: University of Cincinnati College of Medicine, Cincinnati, OH, 2004.

BA: Thomas More College, Crestview Hills, KY, 1997.

Krawczeski C, Vandevoorde R, Kathman T, Bennett M, Woo J, Wang Y, Griffiths R, Devarajan P. Serum Cystatin C Is an Early Predictive Biomarker of Acute Kidney Injury after Pediatric Cardiopulmonary Bypass. CJASN. 2010; 2010 Sep;5(9):1552-7.

Bagshaw SM, Bennett M, Haase M, Haase-Fielitz A, Egi M, Morimatsu H, D'amico G, Goldsmith D, Devarajan P, Bellomo R. Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Intensive Care Med. 2009;36(3):381-4

Stella CL, Bennett MR, Devarajan P, Greis K, Wyder M, Macha S, Rao M, Jodicke C, Moussa H, How HY, Myatt L, Webster R, Sibai BM. Preterm labor biomarker discovery in serum using 3 proteomic profiling methodologies. Am J Obstet Gynecol. 2009;201(4):387.e1-13.

Haase M, Bellomo R, Devarajan P, Ma Q, Bennett MR, Möckel M, Matalanis G, Dragun D, Haase-Fielitz A. Novel biomarkers early predict the severity of acute kidney injury after cardiac surgery in adults. Ann Thorac Surg. 2009;88(1):124-30

Haase-Fielitz A, Bellomo R, Devarajan P, Bennett M, Story D, Matalanis G, Frei U, Dragun D, Haase M. The predictive performance of plasma neutrophil gelatinase-associated lipocalin (NGAL) increases with grade of acute kidney injury. Nephrol Dial Transplant. 2009;24:3349-3354.

Bennett M, Ravipati N, Ross G, Nguyen M, Hirsch R, Beekman R, Rovner L, Devarajan P. Using proteomics to identify pre-procedural risk factors for contrast induced nephropathy. Proteomics – Clinical Applications. 2008;2(7-8):1058-1064.

Koyner JL, Bennett MR, Worcester EM, Ma Q, Raman J, Jeevanandam V, Kasza KE, O'Connor MF, Konczal DJ, Trevino S, Devarajan P, Murray PT. Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int. 2008;74(8):1059-1069.

Lavery AP, Meinzen-Derr JK, Anderson E, Ma Q, Bennett MR, Devarajan P, Schibler KR. Urinary NGAL in premature infants. Pediatr Res. 2008;64(4):423-8.

Bennett M, Dent C, Ma Q, Dastrala S, Grenier F, Workman R, Syed H, Ali S, Barasch J, Devarajan P. Urine NGAL predicts acute kidney injury, morbidity and mortality after cardiac surgery: a prospective study. Clinical Journal of the American Society of Nephrology. 2008;3(3): 665-673.

Bennett M, Czech K, Arend L, Witte D, Devarajan P, Potter, S. Analysis of the glomerular gene expression profile in patients with focal segmental glomerulosclerosis. Experimental Nephron. 2007;107(1): e30-40

Suzuki M, Ross GF, Wiers K, Nelson S, Bennett MR, Passo MH, Devarajan P, Brunner HI. Identification of a urinary proteomic signature for lupus nephritis. Pediatric Nephrology. 2007;22(12): 2047-2057.

Bradley P. Dixon, MD Director, Nephrology Clinical Laboratory

focuses on the recognition and repair of DNA damage within the urinary microenvironment, specifically as it relates to the increased risk of malignancy in the augmented bladder. Dr. Dixon also has clinical and translational research interests in complement-mediated diseases such as atypical hemolytic uremic syndrome, as well as cystic kidney diseases such as tuberous sclerosis and polycystic kidney disease.
Visit the Dixon Lab.

513-636-4531 bradley.dixon@cchmc.org

High Res

Bradley P. Dixon, MD

Director, Nephrology Clinical Laboratory

Pediatric Nephrologist, Division of Nephrology and Hypertension

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-636-4531

Fax 513-636-7407

Email bradley.dixon@cchmc.org

Show All

DNA damage response; DNA repair; hyperosmolal microenvironments; atypical hemolytic uremic syndrome; thrombotic microangiopathies; complement-mediated renal diseases.

Visit the Dixon Lab.

Biography

Bradley Dixon, MD, joined the faculty in the Division of Nephrology and Hypertension at Cincinnati Children's within the UC College of Medicine in 2006. He has received support for his research from a William Cooper Procter Pediatric Research Award in 2006, a Child Health Research Career Development Award (K12) in 2009, and is currently funded by a K08 through the National Institute of Diabetes, Digestive and Kidney Diseases. Dr. Dixon’s research interests focus on the effects of hyperosmolal microenvironments such as the renal medulla and urinary bladder upon vital cellular processes such as the DNA damage response pathway and activation of cell cycle checkpoints and apoptosis. This research focus attempts to understand the susceptibility of the gastrointestinal tissues used in bladder reconstructions to carcinogenesis.

In addition to his basic science research interests, Dr. Dixon has a clinical research interest in thrombotic microangiopathies such as atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP), and is an investigator in a number of clinical trials and registries for these diseases. Dr. Dixon is also involved in clinical research studying cystic kidney diseases such as autosomal dominant polycystic kidney disease (ADPKD).

BA: College of Wooster, Wooster, OH, 1995.

MD: University of Tennessee, Memphis, 1999.

Residency: Cincinnati Children's Hospital Medical Center, 1999-2002.

Chief Residency: Cincinnati Childrens Hospital Medical Center, 2002-2003.

Fellowship: Cincinnati Childrens Hospital Medical Center, 2003-2006.

Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, Davies SM, Pluthero FG, Lu L, Laskin BL. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013 Sep 19;122(12):2003-7.

Siroky BJ, Yin H, Babcock JT, Lu L, Hellmann AR, Dixon BP, Quilliam LA, Bissler JJ. Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress. Am J Physiol Renal Physiol. 2012 Sep 15;303(6):F831-44.

Dixon BP, Henry J, Siroky BJ, Chu A, Groen PA, Bissler JJ. Cell Cycle Control and DNA Damage Response of Conditionally Immortalized Urothelial Cells. PLoS ONE. 2011 Jan 28;6(1):e16595.

Dixon BP, Hulbert JC, Bissler JJ. Tuberous sclerosis complex renal disease. Nephron Exp Nephrol. 2011;118(1):e15-20.

Lo MM, Mo JQ, Dixon BP, Czech KA. Disseminated histoplasmosis associated with hemophagocytic lymphohistiocytosis in kidney transplant recipients. Am J Transplant. 2010 Mar;10(3):687-91.

Dixon BP, Chu A, Henry J, Kim R, Bissler JJ. Increased cancer risk of augmentation cystoplasty: possible role for hyperosmolal microenvironment on DNA damage recognition. Mutat Res. 2009 Nov 2;670(1-2):88-95.

Dixon BP, Lu L, Chu A, Bissler JJ. RecQ and RecG helicases have distinct roles in maintaining the stability of polypurine.polypyrimidine sequences. Mutat Res. 2008 Aug 25;643(1-2):20-8.

Dixon BP, McEnery P, Goebel J. Immunobiology of paediatric renal transplantation. Progress in Paediatric Urology. 2008;10:165-182.

Bissler JJ, Dixon BP. A mechanistic approach to inherited polycystic kidney disease. Pediatr Nephrol. 2005 May;20(5):558-66.

Dixon BP, Devarajan P, Mitsnefes M. Neonatal renovascular hypertension due to prenatal traumatic retroperitoneal hematoma. Pediatr Nephrol. 2005 May;20(5):670-2.

Elif Erkan, MD, MS Pediatric Nephrologist, Division of Nephrology

is a physician scientist whose research interests are proteinuria induced injury in the kidney and the mechanism of albumin endocytosis in the proximal tubule epithelial cells. Her laboratory studies the protein-protein interactions between endocytic receptors/adapters and protein kinases that are involved in cell signaling events.

513-636-4531 elif.erkan@cchmc.org

High Res

Elif Erkan, MD, MS

Pediatric Nephrologist, Division of Nephrology

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-636-4531

Email elif.erkan@cchmc.org

Show All

Clinical & Research Interests

Clinical

Proteinuria; nephrotic syndrome.

Research

Proteinuria induced tubular injury; tubular apoptosis; albumin endocytosis.

Biography

Dr. Elif Erkan received the prestigious SPR Fellow's Basic Research Award upon completion of her pediatric nephrology fellowship. She pursued a career as a physician scientist and continued to investigate the mechanism of proteinuria induced injury in proximal tubule cells following her fellowship. Her laboratory demonstrated an important link between endocytic adapter protein disabled-2 (Dab2) that binds to the cytoplasmic tail of albumin receptor megalin and protein kinase B (Akt). She received an NIH career development-KO8 award to support her studies elucidating the link between albumin endocytosis and cell signaling events.

MD: Ankara University School of Medicine, Ankara, Turkey, 1990.

Residency: Pediatrics, Marmara University Hospital, Istanbul, Turkey, 1992-1997.

Residency: Pediatrics, Montefiore Medical Center, Albert Einstein School of Medicine, Bronx, NY, 2000-2002.

Fellowship: Pediatric Nephrology, Montefiore Medical Center, Albert Einstein School of Medicine, Bronx, NY, 1997-2000.

MS: Clinical Research Methods Montefiore Medical Center, Albert Einstein School of Medicine, Bronx, NY, 1998-2001.

Erkan E. Proteinuria: It is time to look beyond the proximal tubule. Am J Physiol Renal Physiol. 2013 Oct:305(8):F1107-8.

Erkan E. Proteinuria and progression of glomerular diseases. Pediatr Nephrol. 2013 Jul;28(7):1049-58.

Koral K, Erkan E. Pkb/Akt partners with Dab2 in albumin endocytosis. Am J Physiol Renal Physiol. 2012 Apr 15;302(8): F1013-24.

Keyel PA, Thieman JR, Roth R, Erkan E, Everett ET, Watkins SC, Heuser JE, Traub LM. The AP-2 adaptor beta2 appendage scaffolds alternate cargo endocytosis. Mol Biol Cell. 2008 Dec;19(12):5309-26.

Erkan E, Devarajan P, Schwartz G. Mitochondria are the major targets in albumin induced apoptosis in proximal tubule cells. J Am Soc Nephrol. 2007 Apr;18(4): 1199-208.

Erkan E, Devarajan P, Schwartz G. Apoptotic responses to albumin overload: proximal vs. distal/collecting tubule cells. Am J Nephrol. 2005 Mar-Apr;25(2):121-31.

Erkan E, Garcia C, Patterson LT, Mishra J, Mitsnefes MM, Kaskel FJ, Devarajan P. Induction of renal tubular cell apoptosis in FSGS: Roles of proteinuria and Fas-dependent pathways. J Am Soc Nephrol. 2005 Feb;16(2): 398-407.

Erkan E, Sakarcan A, Haklar G, Yalcin S. Thyroxine prevents reoxygenation injury in isolated proximal tubule cells. Pediatr Nephrol. 2003 Jul;18(7): 636-43.

Erkan E, Devarajan P, Kaskel F. Role of nitric oxide, endothelin-1, and inflammatory cytokines in blood pressure regulation in hemodialysis patients. Am J Kidney Dis. 2002 Jul;40(1):76-8.1

Erkan E, Moritz M, Kaskel F. Impact of residual renal function in children on hemodialysis. Pediatr Nephrol. 2001 Nov;16(11): 858-61.

Stuart L. Goldstein, MD, FAAP, FNKF Director, Center for Acute Care Nephrology

focuses on all aspects of acute kidney injury (AKI) spanning from translational work in AKI biomarker validation to long-term AKI epidemiology and outcomes. He is specifically interested in improving outcomes in the critically ill child with or at risk for AKI.

513-803-3295 stuart.goldstein@cchmc.org

High Res

Stuart L. Goldstein, MD, FAAP, FNKF

Director, Center for Acute Care Nephrology

Medical Director, Pheresis Service

Co-Medical Director, Heart Institute Research Core

Medical Director, Dialysis Unit

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-803-3295

Fax 513-636-6407

Email stuart.goldstein@cchmc.org

Show All

Clinical & Research Interests

Clinical

Acute kidney injury; continuous renal replacement therapy; cardio-renal syndrome; nephrotoxic medication associated morbidity

Research

Acute kidney injury epidemiology and biomarkers; heart failure associated chronic kidney disease; nephrotoxic medication associated acute kidney injury reduction

Biography

Stuart L. Goldstein, MD, has been an active investigator in the field of pediatric acute kidney injury (AKI) since 2000. Dr. Goldstein’s main research foci include: AKI epidemiology and outcomes, acute renal replacement therapy provision and investigation of novel urinary AKI biomarkers in the pediatric population. Dr. Goldstein has established a strong record of interdisciplinary and inter-institutional collaboration with cardiologists, intensivists and emergency center physicians, which is evidenced by his establishment and directing of the Prospective Pediatric Continuous Renal Replacement Therapy Registry from 2001 to 2012, and the Prospective Pediatric AKI Research Group (ppAKI-RG) in 2012. The ppAKI-RG is comprised of 39 centers from around the world with the goal of improving outcomes for the child with or at-risk for, AKI.

Dr. Goldstein has led initial efforts to develop a standardized definition for pediatric AKI, assess novel AKI biomarkers in heterogeneous populations, and conceiving and validating stratification tools to identify patients at risk for AKI. Building up these findings, Dr. Goldstein embarked on establishing the ppAKI-RG consortium to focus on multi-centered research studies that are dedicated to understanding and treating AKI in pediatric patients. Currently, the ppAKI-RG has initiated three major, and unprecedented, national and international studies (AWARE, NINJA and DIRECT) to reduce AKI and improve patient outcomes. Dr. Goldstein is also a recognized educator; he has developed the only pediatric specific acute care nephrology sub-specialty fellowship with graduates who are now leaders in the field of pediatric AKI.

MD: Columbia College of Physicians and Surgeons, New York, NY, 1990.

Residency: Baylor College of Medicine, Houston, TX.

Fellowship: Pediatric Nephrology, Children's Hospital, Boston, MA.

Grants

Inflammation, malnutrition and cardiac calcification in pediatric ESRD patients receiving dialysis. Principal Investigator. Casey Lee Ball Foundation. Jan 2010–Dec 2020.

Use of NGAL to Optimize Fluid Dosing, CRRT Initiation and Discontinuation in Critically Ill Children with Acute Kidney Injury. Principal Investigator. Gambro Renal Products. Nov 2011-Jan 2017.

Clinical Evaluation of the Prismaflex™ HF20 Set and Prismaflex™Control Unit Version 5.10 Software for Acute Continuous Renal Replacement Therapy (CRRT) in Children. Principal Investigator. Gambro Renal Products, Inc. Mar 2014–Mar 2016.

Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care. Principal Investigator. NICHD Pediatric Trials Network-POPS. Feb 2013–Feb 2017.

Antibiotic Safety in Infants with Complicated Intra-Abdominal Infections (SCAMP Trial). Principal Investigator. NICHD-2013-ABS01 Pediatric Trials Network. May 2014–Sep 2017.

Recombinant Erythropoietin Protects Against Kidney Disease. Principal Investigator. National Institutes of Health. Sep 2014–Aug 2019.

Reduction of Nephrotoxic Medication Associated Acute Kidney Injury in Children: Dissemination of a Successful Quality Improvement Project. Principal Investigator. Agency for Healthcare Research and Quality. Apr 2015–Mar 2018.

David K. Hooper, MD, MS Medical Director of Kidney Transplantation

aims to improve clinical outcomes for pediatric kidney transplant recipients through research in personalized care and the design of systems capable of delivering that care with high reliability. His primary focus is the prevention of cardiovascular disease through a combination of quality improvement and clinical/translational research methods.

513-636-4531 david.hooper@cchmc.org

High Res

David K. Hooper, MD, MS

Medical Director of Kidney Transplantation

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-636-4531

Fax 513-636-7407

Email david.hooper@cchmc.org

Show All

Nephrology; kidney transplantation; quality improvement

Biography

Jointly appointed in the Division of Nephrology and Hypertension and the James M. Anderson Center for Health Systems Excellence at Cincinnati Children’s Hospital Medical Center within the UC Department of Pediatrics, Dr. Hooper's aim is to improve clinical outcomes for pediatric kidney transplant recipients through research in personalized care and the design of reliable healthcare systems.

Dr. Hooper's research training includes a master's degree in clinical and translational research from the University of Cincinnati, in addition to advanced training in quality improvement methodology through the Quality Scholars in Healthcare Transformation program at Cincinnati Children’s.

Dr. Hooper's career focus is to combine clinical outcomes research with quality improvement to reliably prevent cardiovascular disease, the leading cause of long-term death and disability in pediatric transplant recipients.

MD: University of Utah, Salt Lake City, Utah, 2003.

Residency: Cincinnati Children's Hospital, Cincinnati, Ohio, 2006.

Chief Residency: Cincinnati Children's Hospital, Cincinnati, Ohio, 2007.

MS: University of Cincinnati, Cincinnati, Ohio, 2010.

Fellowship: Cincinnati Children's Hospital, Cincinnati Ohio, 2010; Quality Scholar in Healthcare Transformation, James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital, Cincinnati, Ohio, 2011.

Certification: Pediatrics, 2006.

Hooper DK, Kirby C, Margolis P, Goebel J. Reliable Individualized Monitoring Improves Cholesterol Control in Kidney Transplant Recipients. Pediatrics. 2013 Apr;131(4):e1271-9.

Hooper DK, Williams JC, Carle AC, Amaral S, Chand DH, Ferris ME, Patel HP, Licht C, Barletta GM, Bastian V, Mitsnesfes M, Patel UD. The Quality of Cardiovascular Disease Care and Formal Transition for Adolescents with Kidney Disease. Pediatr Nephrol. 2013 Jun;28(6):939-49.

Hooper DK, Fukuda T, Logan B, Gardiner R, Roy-Chaudhury A, Kirby C, Vinks A, Goebel J. Risk of Tacrolimus Toxicity in CYP3A5 Non-Expressors Treated with Intravenous Nicardipine After Kidney Transplantation. Transplantation. 2012 Apr;93(8):806-812.

Saldaña SN, Hooper DK, Froehlich TE, Campbell KM, Prows CA, Sadhasivam s, Nick TG, Seid M, Vinks AA, Glauser TA. Characteristics of Successful Recruitment in Prospective Pediatric Pharmacogenetic Studies. Clinical Therapeutics. 2011 Feb;15:88-95.

Hooper DK, Carle AC, Schuchter J, Goebel J. Interaction between tacrolimus and intravenous nicardipine in the treatment of post-kidney transplant hypertension at pediatric hospitals. Pediatr Transplant. 2011 Feb;15(1):88-95.

Kaplan HC, Brady PW, Dritz MC, Hooper DK, Linam WM, Froehle CM, Margolis P. The influence of context on quality improvement success in health care: a systematic review of the literature. Milbank Q. 2010 Dec;88(4):500-59.

Hooper DK. The Impact of CYP3A5 Genotype on the Interaction Between Tacrolimus and Intravenous Nicardipine in Kidney Transplant Recipients. University of Cincinnati. 2010 Aug 17.

Hooper DK, Hawkins JA, Fuller TC, Profaizer T, Shaddy RE. Panel-reactive antibodies late after allograft implantation in children. Ann Thorac Surg. 2005 Feb;79(2):641-4.

Raetz EA, Kim MK, Moos P, Carlson M, Bruggers C, Hooper DK, Foot L, Liu T, Seeger R, Carroll WL. Identification of genes that are regulated transcriptionally by Myc in childhood tumors. Cancer. 2003 Aug 15;98(4):841-53.

Lirazan MB, Hooper D, Corpuz GP, Ramilo CA, Bandyopadhyay P, Cruz LJ, Olivera BM. The spasmodic peptide defines a new conotoxin superfamily. Biochemistry. 2000 Feb 22;39(7):1583-8.

Elizabeth C. Jackson, MD Director, Healthy Bladder Clinic

has clinical research in types of bedwetting alarms that are useful for nocturnal enuresis, in outcomes of neurogenic bladder, and in the relationship of obesity and kidney stones as well as industry sponsored research in anticholinergics for neurogenic bladder.

513-636-4975 pedsurology@cchmc.org

High Res

Elizabeth C. Jackson, MD

Director, Healthy Bladder Clinic

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-636-4975

Fax 513-636-6753

Email pedsurology@cchmc.org

Show All

Functional bladder disorders; neurogenic bladder; urolithiasis

Biography

Elizabeth C. Jackson, MD, is a pediatric nephrologist recognized in the need for bladder management. Dr. Jackson has recently discontinued her inpatient nephrology role and is currently focused on outpatient lower urinary tract management. She is the director of the Healthy Bladder Clinic at Cincinnati Children's. The Healthy Bladder Clinic cares for children with functional lower urinary tract disorders. There are more than 1200 visits per year to this clinic.

MD: University of Virginia, Charlottesville, VA, 1978.

Residency: Children's Hospital of Pittsburgh, Pittsburgh, PA, 1981.

Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1984.

Certification: Pediatrics, 1983; Pediatric Nephrology, 1985.

Ivancić V, Defoor W, Jackson E, Alam S, Minevich E, Reddy P, Sheldon C. Progression of renal insufficiency in children and adolescents with neuropathic bladder is not accelerated by lower urinary tract reconstruction. J Urol. 2010 Oct;184(4 Suppl):1768-74.

DeFoor WR, Jackson E, Minevich E, Caillat A, Reddy P, Sheldon C, Asplin J. The risk of recurrent urolithiasis in children is dependent on urinary calcium and citrate. Urology. 2010 Jul;76(1):242-5.

DeFoor W, Clark C, Jackson E, Reddy P, Minevich E, Sheldon C. Risk factors for end stage renal disease in children with posterior urethral valves. J Urol. 2008 Oct;180(4 Suppl):1705-8; discussion 1708.

DeFoor W, Minevich E, Jackson E, Reddy P, Clark C, Sheldon C, Asplin J. Urinary metabolic evaluations in solitary and recurrent stone forming children. J Urol. 2008 Jun;179(6):2369-72.

DeFoor W, Asplin J, Jackson E, Jackson C, Reddy P, Sheldon C, Erhard M, Minevich E. Urinary metabolic evaluations in normal and stone forming children. J Urol. 2006 Oct;176(4 Pt 2):1793-6.

Defoor W, Asplin J, Jackson E, Jackson C, Reddy P, Sheldon C, Minevich E. Results of a prospective trial to compare normal urine supersaturation in children and adults. J Urol. 2005 Oct;174(4 Pt 2):1708-10.

Jensen S, Jackson EC, Riley L, Reddy S, Goebel J. Tacrolimus-based immunosuppression with steroid withdrawal in pediatric kidney transplantation -- 4-year experience at a moderate-volume center. Pediatr Transplant. 2003 7:119-124.

Strife CF, Prada AL, Clardy CW, Jackson E, Forristal J. Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis. J Pediatr. 1990 May;116(5):S98-102.

Paul T. McEnery, MD, MBA Professor Emeritus

has focused his career on the research of membranoproliferative glomerulonephritis and is a key member of the North American Pediatric Renal Transplant Consortium data base. Besides his research in transplantation and immune-mediated renal disease, he also was responsible for bringing the Ronald McDonald House to Cincinnati Children's as well as initiating dialytic therapy for children in Cincinnati.

paul.mcenery@cchmc.org

Paul T. McEnery, MD, MBA

Professor Emeritus

Academic Affiliation

Professor Emeritus, UC Department of Pediatrics

Email paul.mcenery@cchmc.org

Show All

Clinical Interests

Glomerulonephritis; vitamin D resistant rickets; care of the child with end-stage renal disease.

MD: Loyola University, Chicago, IL, 1965.

Residency: Children's Hospital Medical Center, Cincinnati, OH.

Fellowship: Nephrology, Children's Hospital Medical Center, Cincinnati, OH.

Certification: Pediatrics 1974, 1986, 1993; Pediatric Nephrology, 1974, 1986, 1993.

MBA: Xavier University, 1989.

DeFoor W, Tackett L, Minevich E, McEnery P, Kitchens D, Reeves D, Sheldon C. Successful renal transplantation in children with posterior urethral valves. J Urol. 2003 Dec;170(6 Pt 1):2402-4.

Mitsnefes M, Ho PL, McEnery PT. Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). J Am Soc Nephrol. 2003 Oct;14(10):2618-22.

DeFoor W, Minevich E, McEnery P, Tackett L, Reeves D, Sheldon C. Lower urinary tract reconstruction is safe and effective in children with end stage renal disease. J Urol. 2003 Oct;170(4 Pt 2):1497-500; discussion 1500.

Mitsnefes MM, Khoury PR, McEnery PT. Early posttransplantation hypertension and poor long-term renal allograft survival in pediatric patients. J Pediatr. 2003 Jul;143(1):98-103.

Mitsnefes MM, Khoury P, McEnery PT. Body mass index and allograft function in pediatric renal transplantation. Pediatr Nephrol. 2002 Jul;17(7):535-9.

Omoloja AA, Racadio JM, McEnery PT. Post-biopsy renal arteriovenous fistula. Pediatr Transplant. 2002 Feb;6(1):82-5.

Mitsnefes MM, Omoloja A, McEnery PT. Short-term pediatric renal transplant survival: blood pressure and allograft function. Pediatr Transplant. 2001 Jun;5(3):160-5.

Schurman SJ, McEnery PT. Factors influencing short-term and long-term pediatric renal transplant survival. J Pediatr. 1997 Mar;130(3):455-62.

McEnery PT. Pediatric renal transplantation: A review of data from north American pediatric renal transplant cooperative study (NAPRTCS). Saudi J Kidney Dis Transpl. 1994 July-September;5(3):336-46.

McEnery PT, Alexander SR, Sullivan K, Tejani A. Renal transplantation in children and adolescents: the 1992 annual report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol. 1993 Dec;7(6):711-20.

Mark M. Mitsnefes, MD, MS Director, Clinical and Translational Research Center

is an established clinical investigator with expertise in the area of understanding the development of risk factors for cardiovascular disease in children with chronic kidney disease. The long-term goal of his research is to define biologic targets for interventions to prevent and slow progression of cardiovascular disease in children with chronic kidney disease.

513-636-0125 mark.mitsnefes@cchmc.org

High Res

Mark M. Mitsnefes, MD, MS

Director, Clinical and Translational Research Center

Pediatric Nephrologist, Division of Nephrology

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-0125

Fax 513-636-7407

Email mark.mitsnefes@cchmc.org

Show All

Nephrology with focus on chronic kidney disease and hypertension

Biography

Mark Mitsnefes, MD, MS, is an established clinical investigator with expertise in the area of understanding the development of risk factors for cardiovascular disease in children with chronic kidney disease. The long-term goal of his research is to define biologic targets for interventions to prevent and slow progression of cardiovascular disease in children with chronic kidney disease.

Dr. Misnefes has received numerous awards, including the Proctor Scolar Award (Cincinnati Children's Research Foundation), the Pediatrician Scientist Award (Children's Health Research Center, NIH), the Clinical Scientist Award (National Kidney Foundation), and has been ranked as one of the Best Doctors in America, 2007-2011.

MD: Gorky Medical Institute, Gorky, Russia, 1985.

Residency: Miami Children's Hospital, Miami, FL, 1997.

Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2000.

MS: Epidemiology and Biostatistics, University of Cincinnati, Cincinnati, OH, 2001.

Certifications: Educational Commission for Foreign Medical Graduates (ECFMG), 1995; Pediatrics, 1996; Pediatric Nephrology, 2001, 2008.

Mitsnefes M, Flynn J, Cohn S, Samuels J, Blydt-Hansen T, Saland J, Kimball T, Furth S, Warady B; CKiD Study Group. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol. 2010 Jan;21(1):137-44.

Wilson AC, Mitsnefes MM. Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management. Am J Kidney Dis. 2009 Aug;54(2):345-60. Review.

Flynn JT, Mitsnefes MM, Pierce C, Cole SR, Parekh RS, Furth SL and Warady BA. Blood pressure in children with chronic kidney disease: Preliminary findings from chronic kidney disease in children cohort study. Hypertension. 2008;52(4):631-7

Weaver DJ Jr, Kimball T, Witt SA, Glascock BJ, Khoury PR, Kartal J, Mitsnefes MM. Subclinical systolic dysfunction in pediatric patients with chronic kidney disease. J Pediatr. 2008 Oct;153(4):565-9.

Weaver DJ Jr., Kimball TR, Knilans T, Mays WK, Knecht T, Gerdes YT, Witt S, Glascock BJ, Kartal J, Khoury PR, and Mitsnefes MM. Decreased maximal aerobic capacity in pediatric chronic kidney disease. J Am Soc Nephrol. 2008, 19(3):624-30.

Mitsnefes MM, Kimball TR, Kimball TR, Witt SA, Glascock BJ, Khoury PR, and Daniels SR. Abnormal carotid artery structure and function in children with successful renal transplant. Circulation. 2004; 110:97-101.

Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock B, Khoury PR, Daniels SR. Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: Role of calcium-phosphorus metabolism. J Am Soc Nephrol. 2005;16:2796-2803.

Mitsnefes MM, Kimball TR, Border WL, Witt SA, Glascock BJ, Khoury PR and Daniels SR. Impaired left ventricular diastolic function in children with chronic renal failure. Kidney Int. 2004;65(4):1461-1466.

Mitsnefes MM, Kimball TR, Witt SA, Glascock BJ, Khoury PR, and Daniels SR. Left ventricular mass and systolic performance in pediatric patients with chronic renal failure. Circulation. 2003;107:864-868

Mitsnefes MM, Daniels SR, Schwartz SM, Khoury P, Meyer RA, and Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol. 2000;14:898-902.

Grants

Cardiovascular disease in children with CKD. Principal Investigator. National Institutes of Health. 2011 - 2016. #K24 DK090070-01.

Edward J. Nehus, MD, MS Pediatric Nephrologist, Division of Nephrology

is a pediatric nephrologist who has conducted clinical research in chronic kidney disease and critical care nephrology. His primary area of research is studying pharmacokinetic alterations in critically ill children receiving continuous renal replacement therapy. Other research interests include studying cardiovascular risk factors and glomerular filtration rate estimation in children with chronic kidney disease.

513-636-4531 edward.nehus@cchmc.org

High Res

Edward J. Nehus, MD, MS

Pediatric Nephrologist, Division of Nephrology

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-636-4531

Email edward.nehus@cchmc.org

Show All

Critical care nephrology; chronic kidney disease

Biography

Edward conducted and published a cross-sectional study which investigated the association of serum resistin with cardiovascular risk factors in children with chronic kidney disease. In addition, he recently published a study evaluating the outcomes steroid-avoidance protocols in pediatric kidney transplant recipients. He continues to be the primary investigator for ongoing studies that explore pharmacokinetic alterations in critically ill children receiving continuous renal replacement therapy.

MD: University of Toledo, Toledo, OH, 2002.

MS: University of Cincinnati, Cincinnati, OH, 2011.

Residency: Pediatrics, Nationwide Children’s Hospital, Columbus, OH.

Certification: Pediatrics, 2009.

Fellowship: Pediatric Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

Nehus E, Goebel J, Abraham E. Outcomes of steroid-avoidance protocols in pediatric kidney transplant recipients. Am J Transplant. 2012 Dec;12(12):3441-8.

Nehus E, Furth S, Warady B, Mitsnefes M. Correlates of resistin in children with chronic kidney disease: the chronic kidney disease in children cohort. J Pediatr. 161(2): 276-80, 2012.

Nehus E, Goebel J, Mitsnefes M, Lorts A, Laskin B. Intensive hemodialysis for cardiomyopathy associated with end-stage renal disease. Pediatr Nephrol. 26: 1909-12, 2011.

Nehus E, Devarajan P. Acute kidney injury: AKI in kidney transplant recipients—here to stay. Nat Rev Nephrol. 8:198-199, 2012.

Brian J. Siroky, PhD Member, Division of Nephrology

focuses on understanding the mechanisms of renal cyst and tumor formation that occur in tuberous sclerosis complex (TSC), and identification of targeted therapies for these lesions. Structural and functional relationships between renal epithelial primary cilia (specialized cellular organelles whose dysfunction is linked to cystogenesis) and mTOR signaling, the pathway that is dysregulated in TSC is also an area of interest.

513-636-4497 brian.siroky@cchmc.org

C. Frederic Strife, MD

has focused his research career around immune-mediated renal disease and membranoproliferative glomerulonephritis in particular. Furthermore, Dr. Strife also has been active in understanding how to improve the care of the pediatric dialysis patient.

fred.strife@cchmc.org

C. Frederic Strife, MD

Academic Affiliations

Emeritus, UC Department of Pediatrics

Email fred.strife@cchmc.org

Show All

Clinical Interests

Glomerulonephritis; renal tubular disorders; growth failure in chronic renal disease; dialysis

MD: College of Medicine and Dentistry of New Jersey, 1968.

Residency: Pediatrics, Children's Hospital Medical Center, Cincinnati, OH.

Fellowship: Nephrology, Children's Hospital Medical Center, Cincinnati, OH.

Certification: Pediatrics, 1973; Pediatric Nephrology, 1976.